| Genomic classification and prognosis in acute myeloid leukemia E Papaemmanuil, M Gerstung, L Bullinger, VI Gaidzik, P Paschka, ... New England Journal of Medicine 374 (23), 2209-2221, 2016 | 4150 | 2016 |
| Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial KC Wollert, GP Meyer, J Lotz, SR Lichtenberg, P Lippolt, C Breidenbach, ... The Lancet 364 (9429), 141-148, 2004 | 3211 | 2004 |
| Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation RM Stone, SJ Mandrekar, BL Sanford, K Laumann, S Geyer, ... New England Journal of Medicine 377 (5), 454-464, 2017 | 2262 | 2017 |
| Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia RF Schlenk, K Döhner, J Krauter, S Fröhling, A Corbacioglu, L Bullinger, ... New England Journal of Medicine 358 (18), 1909-1918, 2008 | 2112 | 2008 |
| Retinoic acid and arsenic trioxide for acute promyelocytic leukemia F Lo-Coco, G Avvisati, M Vignetti, C Thiede, SM Orlando, S Iacobelli, ... New England Journal of Medicine 369 (2), 111-121, 2013 | 1724* | 2013 |
| Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months’ follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST … GP Meyer, KC Wollert, J Lotz, J Steffens, P Lippolt, S Fichtner, H Hecker, ... Circulation 113 (10), 1287-1294, 2006 | 1408 | 2006 |
| Monitoring of bone marrow cell homing into the infarcted human myocardium M Hofmann, KC Wollert, GP Meyer, A Menke, L Arseniev, B Hertenstein, ... Circulation 111 (17), 2198-2202, 2005 | 1215 | 2005 |
| Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma A Engert, A Plütschow, HT Eich, A Lohri, B Dörken, P Borchmann, ... New England Journal of Medicine 363 (7), 640-652, 2010 | 1122 | 2010 |
| Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults D Hoelzer, E Thiel, H Loffler, T Büchner, A Ganser, G Heil, P Koch, ... | 775 | 1988 |
| TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome FG Rücker, RF Schlenk, L Bullinger, S Kayser, V Teleanu, H Kett, ... Blood, The Journal of the American Society of Hematology 119 (9), 2114-2121, 2012 | 721 | 2012 |
| Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final … M Lübbert, S Suciu, L Baila, BH Rüter, U Platzbecker, A Giagounidis, ... Journal of clinical oncology 29 (15), 1987-1996, 2011 | 667 | 2011 |
| A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q P Fenaux, A Giagounidis, D Selleslag, O Beyne-Rauzy, G Mufti, ... Blood, The Journal of the American Society of Hematology 118 (14), 3765-3776, 2011 | 575 | 2011 |
| Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease DM Good, P Zürbig, A Argiles, HW Bauer, G Behrens, JJ Coon, M Dakna, ... Molecular & cellular proteomics 9 (11), 2424-2437, 2010 | 561 | 2010 |
| Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase … F Ciceri, C Bonini, MTL Stanghellini, A Bondanza, C Traversari, ... The lancet oncology 10 (5), 489-500, 2009 | 553 | 2009 |
| Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies N Gökbuget, M Kneba, T Raff, H Trautmann, CR Bartram, R Arnold, ... Blood, The Journal of the American Society of Hematology 120 (9), 1868-1876, 2012 | 545 | 2012 |
| Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes F Thol, S Kade, C Schlarmann, P Löffeld, M Morgan, J Krauter, ... Blood, The Journal of the American Society of Hematology 119 (15), 3578-3584, 2012 | 543 | 2012 |
| The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML S Kayser, K Doehner, J Krauter, CH Koehne, HA Horst, G Held, ... Blood, The Journal of the American Society of Hematology 117 (7), 2137-2145, 2011 | 533 | 2011 |
| Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation AR Choudhury, Z Ju, MW Djojosubroto, A Schienke, A Lechel, ... Nature genetics 39 (1), 99-105, 2007 | 511 | 2007 |
| Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group J Krönke, RF Schlenk, KO Jensen, F Tschürtz, A Corbacioglu, VI Gaidzik, ... Journal of Clinical Oncology 29 (19), 2709-2716, 2011 | 494 | 2011 |
| Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia F Thol, F Damm, A Lüdeking, C Winschel, K Wagner, M Morgan, H Yun, ... Journal of Clinical Oncology 29 (21), 2889-2896, 2011 | 485 | 2011 |
